NEW YORK--(BUSINESS WIRE)--Medidata (NASDAQ:MDSO), the leading global provider of cloud-based solutions and data analytics for clinical research, today announced that the company has joined the Medical Device Innovation Consortium (MDIC), a non-profit organization dedicated to advancing medical device regulatory science.
MDIC brings together key stakeholders to facilitate dialogue and develop new methods and standards to deliver cutting-edge medical technology to patients, quickly and cost-effectively. Members include the US Food and Drug Administration (FDA), along with non-profit healthcare organizations, industry trade associations and medical device manufacturers.
A top priority within Medidata’s mission of powering smarter treatments and healthier people is to help expedite the development of life-changing medical device technologies. Today, nearly 850 life sciences organizations are leveraging the scale, agility and value provided by Medidata’s end-to-end clinical trial platform, including 16 of the top 20 medical device developers. Becoming a part of MDIC is an illustration of Medidata’s dedication to the medical device industry, as well as the patients who will benefit from more efficient and effective research processes and treatment options.
“Joining MDIC is a natural extension of Medidata’s commitment to healthcare technology companies everywhere,” said Glen de Vries, president of Medidata. "Medical device companies of all sizes face unique challenges when bringing their innovations to market. We're committed to providing them with the right tools, data, and analytics to address their specific needs, and are excited to spur meaningful change alongside MDIC."
“Medidata is a key addition to an already strong roster of MDIC partners,” stated MDIC CEO, Bill Murray. “The breadth and depth of the company’s experience and success with clinical trials in the medical device and diagnostic field is an example of the kind of intellectual capital the ecosystem needs to help transform how new technologies are delivered to patients. We look forward to working with Medidata, alongside our other members, to create high-impact regulatory science tools well into the future.”
Connect with Medidata
- Read our blog, Geeks Talk Clinical
- Tweet this: .@Medidata joins @MDIConline to drive innovation in the #meddevice & #technology space, improving #patient care: http://ow.ly/JP9S309pJCr
- Follow us on Twitter: @Medidata
- Find us on LinkedIn
About Medical Device Innovation Consortium
Founded in 2012, the Medical Device Innovation Consortium (MDIC) is the first public-private partnership created with the sole objective of advancing medical device regulatory science throughout the total product life cycle. MDIC’s mission is to promote public health through science and technology and to enhance trust and confidence among stakeholders. MDIC works in the pre-competitive space to facilitate development of methods, tools and approaches that enhance understanding and improve evaluation of product safety, quality and effectiveness. Consortium initiatives improve product safety and patient access to cutting-edge medical technology while reducing cost and time to market. For more information, visit www.mdic.org.
Medidata is reinventing global drug development by creating the industry's leading cloud-based solutions for clinical research. Through our advanced applications and intelligent data analytics, Medidata helps advance the scientific goals of life sciences customers worldwide, including nearly 850 global pharmaceutical companies, innovative biotech, diagnostic and device firms, leading academic medical centers, and contract research organizations.
The Medidata Clinical Cloud® brings a new level of quality and efficiency to clinical trials that empower our customers to make more informed decisions earlier and faster. Our unparalleled clinical trial data assets provide deep insights that pave the way for future growth. The Medidata Clinical Cloud is the primary technology solution powering clinical trials for 17 of the world's top 25 global pharmaceutical companies, from study design and planning through execution, management and reporting.